NCT03418480View on ClinicalTrials.gov

HARE-40: HPV Anti-CD40 RNA vaccinE

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

April 11, 2017

Primary Completion Date

November 1, 2023

Study Completion Date

January 24, 2024

Conditions
Human Papilloma Virus Related CarcinomaHead and Neck NeoplasmCervical NeoplasmPenile Neoplasms MalignantUnknown Primary Tumors
Interventions
DRUG

BNT113

Intradermal vaccine

Trial Locations (2)

SO16 6YD

Univeristy Hospitals Southampton NHS Foundation Trust, Southampton

M20 4BX

The Christie NHS Foundation Trust, Manchester

Sponsors

Collaborators (1)

BioNTech SE
All Listed Sponsors
collaborator

BioNTech SE

INDUSTRY

lead

University of Southampton

OTHER